Interfacial lipid digestion-responsive injectable nanoemulsions enhance lapatinib efficacy in triple-negative breast cancer.
Lapatinib (LPT), a brick-dust kinase inhibitor, shows slow oral bioavailability and dose-limiting gastrointestinal side effects that frequently lead to therapeutic discontinuation. Increasing oral bioavailability does not mitigate these adverse effects, and developing complex LPT delivery systems is challenging due to...